Panel requires stricter safety criteria for blood system trial

11/17/2009 | Forbes

The FDA's Blood Products Advisory Committee has required Cerus to tighten safety parameters for a late-stage study involving its intercept blood system, which inhibits blood-borne pathogens in blood components used for transfusions. The company said it may take a year to finish preparations for the planned trial.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA